{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:57:16Z","timestamp":1777417036577,"version":"3.51.4"},"reference-count":79,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Aveiro"},{"name":"FCT\/MCTES (Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, Minist\u00e9rio da Ci\u00eancia, da Tecnologia e do Ensino Superior)"},{"name":"FEDER"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Cyclodextrins are often used as molecular carriers for small active ingredients in medicine. Recently, the intrinsic medicinal activity of some of these compounds has been under investigation, mainly related to their ability to interfere with cholesterol and, therefore, prevent and treat cholesterol-related diseases such as cardiovascular disease and neuronal diseases arising from altered cholesterol and lipid metabolism. One of the most promising compounds within the cyclodextrin family is 2-hydroxypropyl-\u03b2-cyclodextrin (HP\u03b2CD), owing to its superior biocompatibility profile. This work presents the most recent advances in the research and clinical use of HP\u03b2CD against Niemann\u2013Pick disease, a congenital condition involving cholesterol accumulation inside lysosomes in brain cells, Alzheimer\u2019s and Parkinson\u2019s. HP\u03b2CD plays a complex role in each of these ailments, going beyond the mere sequestering of cholesterol molecules and involving an overall regulation of protein expression that helps restore the normal functioning of the organism.<\/jats:p>","DOI":"10.3390\/biom13040666","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T02:57:08Z","timestamp":1681268228000},"page":"666","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-970X","authenticated-orcid":false,"given":"Susana Santos","family":"Braga","sequence":"first","affiliation":[{"name":"LAQV-REQUIMTE (Associated Laboratory for Green Chemistry), Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"ref_1","first-page":"69","article-title":"Sur la fermentation de la f\u00e9cule par l\u2019action du ferment butyrique","volume":"112","author":"Villiers","year":"1891","journal-title":"C. R. Acad. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jlac.19355180107","article-title":"\u00dcber Schardingers Dextrine aus St\u00e4rke","volume":"518","author":"Freudenberg","year":"1935","journal-title":"Justus Liebigs Ann. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00253-002-1057-x","article-title":"Enzymatic production of cyclodextrins","volume":"59","author":"Biwer","year":"2002","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biortech.2003.07.007","article-title":"Optimization of cyclodextrin production from sago starch","volume":"92","author":"Charoenlap","year":"2004","journal-title":"Biores. Technol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2200037","DOI":"10.1002\/star.202200037","article-title":"Valorization of potato peels starch for efficient \u03b2-cyclodextrin production and purification through an eco-friendly process","volume":"74","author":"Bouzid","year":"2022","journal-title":"Starch"},{"key":"ref_6","first-page":"464","article-title":"R\u00f6ntgenographische Untersuchungen an Schardinger-Dextrinen","volume":"3","author":"Borchert","year":"1948","journal-title":"Z. Naturforschg. B"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102156","DOI":"10.1016\/j.jddst.2020.102156","article-title":"Technological evolution of cyclodextrins in the pharmaceutical field","volume":"61","author":"Riascos","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Aiassa, Z., Garnero, C., Longhi, M.R., and Zoppi, A. (2021). Cyclodextrin multicomponent complexes: Pharmaceutical applications. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071099"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Braga, S.S., Barbosa, J.S., Santos, N.E., El-Saleh, F., and Paz, F.A.A. (2021). Cyclodextrins in antiviral therapeutics and vaccines. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030409"},{"key":"ref_10","unstructured":"Ramirez, F.G. (2015). Cyclodextrins: Synthesis, Chemical Applications and Role in Drug Delivery, NovaSience. [1st ed.]. Chapter 6."},{"key":"ref_11","unstructured":"European Medicines Agency (2014). Background Review for Cyclodextrins Used as Excipients, EMA. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2014\/12\/WC500177936.pdf."},{"key":"ref_12","unstructured":"(2004). Office of Food Additive Safety, Center for Food Safety and Applied Nutrition (Standard No. Agency Response Letter Gras notice GRN No. 155)."},{"key":"ref_13","unstructured":"(2001). Office of Food Additive Safety, Center for Food Safety and Applied Nutrition (Standard No. Agency Response Letter Gras notice GRN No. 74)."},{"key":"ref_14","unstructured":"(2000). Office of Food Additive Safety, Center for Food Safety and Applied Nutrition (Standard No. Agency Response Letter Gras notice GRN No. 46)."},{"key":"ref_15","first-page":"3","article-title":"Safety evaluation of certain food additives (\u03b1-cyclodextrin\u2014Addendum)","volume":"54","author":"Kroes","year":"2006","journal-title":"WHO Food Addit. Ser."},{"key":"ref_16","first-page":"257","article-title":"Safety evaluation of certain food additives (\u03b2-cyclodextrin)","volume":"35","author":"Pollit","year":"1996","journal-title":"WHO Food Addit. Ser."},{"key":"ref_17","first-page":"969","article-title":"JEFCA 55th meeting: Safety evaluation of certain food additives and contaminants (\u03b3-cyclodextrin)","volume":"44","author":"Abbott","year":"2000","journal-title":"WHO Food Addit. Ser."},{"key":"ref_18","unstructured":"(2023, March 29). Sporanox\u00ae (Itraconazole) Oral Solution. Available online: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SPORANOX-Oral+Solution-pi.pdf."},{"key":"ref_19","unstructured":"(2023, March 29). Sporanox\u00ae (Itraconazole) Injectable, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020966s017s018s020lbl.pdf."},{"key":"ref_20","unstructured":"(2023, March 29). Veklury\u00ae (Remdesivir) Prescribing Information. Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/covid-19\/veklury\/veklury_pi.pdf."},{"key":"ref_21","unstructured":"(2023, March 29). Clorocil\u00ae. Available online: https:\/\/edol.pt\/en\/produto\/clorocil-10mg-2\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40267-019-00629-5","article-title":"Midazolam oral solution (Ozalin\u00ae): A profile of its use for procedural sedation or premedication before anaesthesia in children","volume":"35","year":"2019","journal-title":"Drug Ther. Persp."},{"key":"ref_23","unstructured":"(2023, March 29). Yaz\u00ae Product Monograph. Available online: https:\/\/www.bayer.com\/sites\/default\/files\/2020-11\/yaz-pm-en.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3311\/PPch.21222","article-title":"Recent list of cyclodextrin-containing products","volume":"67","author":"Szente","year":"2023","journal-title":"Period. Polytech. Chem. Eng."},{"key":"ref_25","first-page":"6177","article-title":"Cyclodextrine\u2014Wundert\u00fcten in Pharmazie und Alltag","volume":"28","author":"Klein","year":"2008","journal-title":"Pharm. Ztg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1021\/jm00111a055","article-title":"Potent inhibitory effect of a series of modified cyclodextrin sulfates (mCDS) on the replication of HIV-1 in vitro","volume":"34","author":"Moriya","year":"1991","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Braga, S.S. (2019). Cyclodextrins, emerging medicines of the new millennium. Biomolecules, 9.","DOI":"10.3390\/biom9120801"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/088922201300343690","article-title":"Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1","volume":"17","author":"Liao","year":"2001","journal-title":"Aids Res. Hum. Retrov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10847-008-9510-9","article-title":"Study of the cholesterol extraction capacity of \u03b2-cyclodextrin and its derivatives, relationships with their effects on endothelial cell viability and on membrane models","volume":"63","author":"Castagne","year":"2009","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_30","first-page":"53","article-title":"The development and regulatory history of sugammadex in the United States","volume":"30","author":"Murphy","year":"2016","journal-title":"APSF Newsl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/EJA.0b013e32833d56b7","article-title":"Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: Results of a randomised, controlled trial","volume":"27","author":"Blobner","year":"2010","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.4049\/jimmunol.1700302","article-title":"Cyclodextrin reduces cholesterol crystal\u2013induced inflammation by modulating complement activation","volume":"199","author":"Bakke","year":"2017","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"333ra50","DOI":"10.1126\/scitranslmed.aad6100","article-title":"Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming","volume":"8","author":"Zimmer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/CIRCULATIONAHA.119.044803","article-title":"Cyclodextrin prevents abdominal aortic aneurysm via activation of vascular smooth muscle cell transcription factor EB","volume":"142","author":"Lu","year":"2020","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int."},{"key":"ref_36","unstructured":"(2023, March 29). FDA Approves Development of VAR 200 for Treatment of FSGS. Available online: https:\/\/www.hcplive.com\/view\/fda-approves-development-var-200-treatment-fsgs."},{"key":"ref_37","unstructured":"(2023, March 29). Zyversa Therapeutics\u2014Pipeline. Available online: https:\/\/www.zyversa.com\/pipeline."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1471-4159.2005.03001.x","article-title":"Protection by cholesterol-extracting cyclodextrins: A role for N-methyl-d-aspartate receptor redistribution","volume":"92","author":"Abulrob","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1523\/JNEUROSCI.0933-21.2021","article-title":"Repeated administration of 2-hydroxypropyl-\u03b2-cyclodextrin (HP\u03b2CD) attenuates the chronic inflammatory response to experimental stroke","volume":"42","author":"Becktel","year":"2022","journal-title":"J. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Aroora, P., and Dhingra, N. (2018). Cyclodextrin\u2014A versatile Ingredient, IntechOpen. Chapter 4.","DOI":"10.5772\/intechopen.69187"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0024-3205(01)01384-4","article-title":"Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease","volume":"70","author":"Camargo","year":"2001","journal-title":"Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1523\/JNEUROSCI.1317-11.2011","article-title":"Unesterified cholesterol accumulation in late endosomes\/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment","volume":"31","author":"Aqul","year":"2011","journal-title":"J. Neurosc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.ymgme.2010.11.148","article-title":"Intrathecal cyclodextrin therapy of feline Niemann-Pick Type C disease","volume":"102","author":"Vite","year":"2011","journal-title":"Mol. Gen. Metabol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Davidson, C.D., Ali, N.F., Micsenyi, M.C., Stephney, G., Renault, S., Dobrenis, K., Ory, D.S., Vanier, M.T., and Walkley, S.U. (2009). Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006951"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/s41419-018-1056-1","article-title":"Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann\u2013Pick C1 mutant cell via lysosome-associated membrane protein 1","volume":"9","author":"Singhal","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.1074\/jbc.M113.506246","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin promotes transcription factor EB-mediated activation of autophagy","volume":"289","author":"Song","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.celrep.2013.10.042","article-title":"Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease","volume":"5","author":"Sarkar","year":"2013","journal-title":"Cell Rep."},{"key":"ref_48","unstructured":"(2022, November 14). Orphanet, Hydroxy-Propyl-Beta-Cyclodextrin. Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=327849."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/S0140-6736(17)31465-4","article-title":"Intrathecal 2-hydroxypropyl-\u03b2-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: A non-randomised, open-label, phase 1\u20132 trial","volume":"390","author":"Ory","year":"2017","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2017.12.014","article-title":"Long-Term Treatment of Niemann-Pick Type C1 Disease with Intrathecal 2-Hydroxypropyl-\u03b2-Cyclodextrin","volume":"80","author":"Chin","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40263-019-00642-2","article-title":"Long-Term Neuropsychological Outcomes from an Open-Label Phase I\/IIa Trial of 2-Hydroxypropyl-\u03b2-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1","volume":"33","author":"Farmer","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_52","unstructured":"(2022, November 14). VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease\u2014NCT02534844, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02534844."},{"key":"ref_53","unstructured":"Van Meter, S., and Mallinckrodt Pharmaceuticals (2022, November 14). Clinical update on intrathecal VTS-270 for the treatment of Niemann-Pick Disease. Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research, 1\u20134 June 2019. Available online: https:\/\/mallinckrodt.gcs-web.com\/static-files\/e0712994-a013-4658-b8be-0a3bc4da0c5b#page=6."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"108125","DOI":"10.1016\/j.heares.2020.108125","article-title":"Cochlear spiral ganglion neuron degeneration following cyclodextrin-induced hearing loss","volume":"400","author":"Ding","year":"2021","journal-title":"Hearing Res."},{"key":"ref_55","unstructured":"(2022, November 14). Message from Mallinckrodt Concerning Adrabetadex Transition. Available online: https:\/\/parseghianfund.nd.edu\/2020\/07\/16\/message-from-mallinckrodt-concerning-adrabetadex-transition\/."},{"key":"ref_56","unstructured":"Quandt, K. (2022, November 14). The FDA Needs to be more Flexible in Assessing Treatments for Rare Diseases, Like the One that Seemed to Help My Son. Available online: https:\/\/www.statnews.com\/2022\/09\/07\/the-fda-needs-to-be-more-flexible-in-assessing-treatments-for-rare-diseases-like-the-one-that-seemed-to-help-my-son\/."},{"key":"ref_57","unstructured":"(2022, November 14). Mandos Health Monthly Communication, May 2022. Available online: https:\/\/mandoshealth.com\/communications\/May_1_2022."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2174\/15672050113106660174","article-title":"Amyloid-\u03b2 peptides, Alzheimer\u2019s disease and the blood-brain barrier","volume":"10","author":"Gosselet","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer\u2019s disease: Genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12035-012-8337-y","article-title":"Role of cholesterol in APP metabolism and its significance in Alzheimer\u2019s disease pathogenesis","volume":"47","author":"Maulik","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-022-05439-w","article-title":"APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes","volume":"611","author":"Blanchard","year":"2022","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/jpet.119.260497","article-title":"Modest blood-brain barrier permeability of the cyclodextrin kleptose\u00ae: Modification by efflux and luminal surface binding","volume":"371","author":"Banks","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41593-022-01127-0","article-title":"Peripheral apoE4 enhances Alzheimer\u2019s pathology and impairs cognition by compromising cerebrovascular function","volume":"25","author":"Liu","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1084\/jem.20121239","article-title":"Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease","volume":"209","author":"Yao","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"P714","DOI":"10.1016\/j.jalz.2012.05.1932","article-title":"Neuroprotective effects of cyclodextrin in Alzheimer\u2019s disease","volume":"8","author":"Yao","year":"2012","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/15548627.2018.1438807","article-title":"Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion","volume":"14","author":"Bartolessis","year":"2018","journal-title":"Autophagy"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0014-5793(94)80467-2","article-title":"\u03b2-Cyclodextrin interacts with the Alzheimer amyloid \u03b2-A4 peptide","volume":"341","author":"Camilleri","year":"1994","journal-title":"FEBS Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0006-291X(02)02337-9","article-title":"NMR and CD studies on the interaction of Alzheimer \u03b2-amyloid peptide (12\u201328) with \u03b2-cyclodextrin","volume":"297","author":"Qin","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1021\/bi036254p","article-title":"Two-site binding of \u03b2-cyclodextrin to the Alzheimer A\u03b2(1\u201340) peptide measured with combined PFG-NMR diffusion and induced chemical shifts","volume":"43","author":"Danielsson","year":"2004","journal-title":"Biochemistry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","article-title":"Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors","volume":"53","author":"Jeong","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jpp\/rgac001","article-title":"Brain uptake and distribution patterns of 2-hydroxypropyl-\u00df-cyclodextrin after intrathecal and intranasal administration","volume":"74","author":"Banks","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.xphs.2016.05.017","article-title":"Neuroprotective effects of engineered polymeric nasal microspheres containing hydroxypropyl-\u03b2-cyclodextrin on \u03b2-amyloid(1-42)\u2013induced toxicity","volume":"105","author":"Yalcin","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_74","unstructured":"(2022, December 22). A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients with Early Alzheimer\u2019s Disease (EAD501), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05607615."},{"key":"ref_75","first-page":"45","article-title":"Mitochondria and Parkinson\u2019s disease: Clinical, molecular, and translational aspects","volume":"11","author":"Borsche","year":"2021","journal-title":"J. Park. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1038\/s41467-022-33252-6","article-title":"Small soluble \u03b1-synuclein aggregates are the toxic species in Parkinson\u2019s disease","volume":"13","author":"Emin","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.28810","article-title":"Parkinson\u2019s disease phenotypes in patient neuronal cultures and brain organoids improved by 2-hydroxypropyl-\u03b2-cyclodextrin treatment","volume":"37","author":"Jarazo","year":"2022","journal-title":"Mov. Disord."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kilpatrick, K., Zeng, Y., Hancock, T., and Segatori, L. (2015). Genetic and chemical activation of TFEB mediates clearance of aggregated \u03b1-synuclein. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120819"},{"key":"ref_79","unstructured":"Jarazo, J.M., Walter, J., and Schwamborn, J.C. (2019). (Inventors) 2-Hydroxypropyl-Beta-Cyclodextrin for Use in a Method of Treatment of a Parkinsonian Condition. (WO2019219741A1), WIPO Patent."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/4\/666\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:17Z","timestamp":1760123657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/4\/666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":79,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["biom13040666"],"URL":"https:\/\/doi.org\/10.3390\/biom13040666","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}